|HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study|
|Sun, Yingxian1; Liu, Xingli2; Guo, Liang1; Pang, Wenyue2; Guo, Xiaofan1; Sun, Zhaoqing2; Li, Zhanquan3; Cui, Xiaoying4; Li, Hui5; Tao, Guizhou6; Wang, Lanfeng7; Zhou, Changyong8; Liu, Ying3; Shan, Hongwei4; Wang, Manqing5; Liu, Mingxin6; Li, Jia7; Yin, Lei8; Hu, Dayi9|
|关键词||Htupa Rt-pa Acute Myocardial Infarction Patency Thrombolysis|
|刊名||INTERNATIONAL JOURNAL OF CARDIOLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Cardiac & Cardiovascular Systems|
|研究领域[WOS]||Cardiovascular System & Cardiology|
|关键词[WOS]||TISSUE-PLASMINOGEN-ACTIVATOR ; SELECTIVE CORONARY THROMBOLYSIS ; DOSE SYNERGISTIC COMBINATIONS ; ACUTE ISCHEMIC-STROKE ; PREHOSPITAL THROMBOLYSIS ; PRIMARY ANGIOPLASTY ; CLINICAL-TRIAL ; 5-HOUR WINDOW ; RT-PA ; UROKINASE|
Background: It is necessary to develop a new thrombolytic agent which can be used by a single bolus at first aid sites to decrease the time to reperfusion in clinical practice. HTUPA, a genetically engineered new thrombolytic with a longer half-life, is well qualified. We aim to compare the thrombolytic efficacy and safety of human tissue urokinase type plasminogen activator (HTUPA) to recombinant tissue plasminogen activator (rt-PA) in Chinese patients with acute myocardial infarction (AMI).
Methods: AMI patients (n = 221) were randomized to rt-PA (a standard protocol) or HTUPA (25 mg bolus) treatment groups. All patients also received oral aspirin and intravenous heparin. Coronary angiography was performed 90 min after therapy initiation to determine infarct-related coronary artery (IRA) patency. Clinical outcomes and changes of clotting variables, heart rate, blood pressure, left ventricular ejection fraction (LVEF), and electrocardiogram were evaluated.
Results: Patent IRA [thrombolysis in myocardial infarction (TIMI) grade 2 or 3] was observed in 77% of HTUPA-treated patients, compared to 76% of rt-PA-treated patients (P = 0.76). TIMI grade 3 patency rates were 52% and 44% in the HTUPA and rt-PA groups, respectively (P = 0.37). The total patency rate was 77% (86/111 patients) in the HTUPA group and 73% (80/110 patients) in the rt-PA group (P = 0.41). Adverse events were infrequent in both groups, and no significant differences were detected in mortality, re-occlusion rate, revascularization rate, adverse effects, clotting index, LVEF, or electrocardiogram between the two groups.
Conclusions: Intravenous HTUPA had a safe and efficacious profile as good as rt-PA in patients with AMI. (C) 2013 Published by Elsevier Ireland Ltd.
|作者单位||1.China Med Univ, Hosp 1, Dept Cardiol, Shenyang 110001, Peoples R China|
2.China Med Univ, Shengjing Hosp, Dept Cardiol, Shenyang 110001, Peoples R China
3.Liaoning Prov Hosp, Dept Cardiol, Shenyang, Peoples R China
4.Inner Mongolia Univ, Dept Cardiol, Affiliated Hosp, Hohhot, Peoples R China
5.Gen Hosp Daqing Oil Field, Dept Cardiol, Daqing, Peoples R China
6.Liaoning Med Coll, Dept Cardiol, Affiliated Hosp, Jinzhou, Peoples R China
7.Harbin Med Univ, Affiliated Hosp 1, Dept Cardiol, Harbin, Peoples R China
8.Qingdao Univ, Sch Med, Affiliated Hosp, Dept Cardiol, Qingdao 266071, Peoples R China
9.Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China
|Sun, Yingxian,Liu, Xingli,Guo, Liang,et al. HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY,2014,172(2):326-331.|
|APA||Sun, Yingxian.,Liu, Xingli.,Guo, Liang.,Pang, Wenyue.,Guo, Xiaofan.,...&Hu, Dayi.(2014).HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study.INTERNATIONAL JOURNAL OF CARDIOLOGY,172(2),326-331.|
|MLA||Sun, Yingxian,et al."HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study".INTERNATIONAL JOURNAL OF CARDIOLOGY 172.2(2014):326-331.|